Published in Gene Therapy Weekly, June 14th, 2001
The intent of the research was to determine the safety and maximum tolerated dose of weekly or every-other-week injections of VNP20009, and to assess the behavior of VNP20009 in a large species that is similar to humans and that develops naturally occurring tumors.
The study demonstrated that VNP20009 was safe to administer on a weekly or every-other-week schedule and also produced significant antitumor...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.